×
Join our live online event
How top hedge funds use news to make money
form the stock market & how ordinary people are
copying their strategies
Register now!
form the stock market & how ordinary people are
copying their strategies
No thanks
JAGX – jaguar health, inc. (US:NASDAQ)
DELAYED
$
| Volume Shares | |
| 1 Day Range | |
| Volume Ratio | |
| 52 Week High | |
| 52 Week Low |
| VWAP | |
| Today’s Volatility | |
| 20 Days Volatility | |
| Open | |
| Prior Close |
1D
5D
1M
3M
YTD
1Y
3Y
1 Day
JAGX
SPY
QQQ
Swipe to see more
Main News & Impact Reports
Date
Time
Symbol
Headline
Impact
11/19
09:46 am
jagx
Jaguar Health Family Company Napo Therapeutics Named “Best Pharmaceuticals Innovator of the Year - Europe” [Yahoo! Finance]
Low
Report
Jaguar Health Family Company Napo Therapeutics Named “Best Pharmaceuticals Innovator of the Year - Europe” [Yahoo! Finance]
11/19
09:30 am
jagx
Jaguar Health Family Company Napo Therapeutics Named “Best Pharmaceuticals Innovator of the Year - Europe”
Medium
Report
Jaguar Health Family Company Napo Therapeutics Named “Best Pharmaceuticals Innovator of the Year - Europe”
11/16
08:06 am
jagx
Jaguar Health Third Quarter 2024 Earnings: EPS Beats Expectations, Revenues Lag [Yahoo! Finance]
Low
Report
Jaguar Health Third Quarter 2024 Earnings: EPS Beats Expectations, Revenues Lag [Yahoo! Finance]
11/14
02:21 am
jagx
Jaguar Health Inc (JAGX) Q3 2024 Earnings Call Highlights: Revenue Growth and Strategic ... [Yahoo! Finance]
Low
Report
Jaguar Health Inc (JAGX) Q3 2024 Earnings Call Highlights: Revenue Growth and Strategic ... [Yahoo! Finance]
11/13
08:00 am
jagx
Jaguar Health Reports Third Quarter 2024 Financial Results
Medium
Report
Jaguar Health Reports Third Quarter 2024 Financial Results
11/11
08:30 am
jagx
Jaguar Health to Hold Investor Webcast Wednesday, November 13th at 8:30 AM Eastern Regarding Q3 2024 Financials & Corporate Updates
Medium
Report
Jaguar Health to Hold Investor Webcast Wednesday, November 13th at 8:30 AM Eastern Regarding Q3 2024 Financials & Corporate Updates
11/6
10:00 am
jagx
FDA Approves Renewal of Canalevia-CA1, Jaguar Health's Drug for Chemotherapy-Induced Diarrhea in Dogs
Low
Report
FDA Approves Renewal of Canalevia-CA1, Jaguar Health's Drug for Chemotherapy-Induced Diarrhea in Dogs
11/4
08:30 am
jagx
Abstract Describing Significant Results of Crofelemer for Cancer Therapy-Related Diarrhea in Breast Cancer Patients Accepted for Presentation at San Antonio Breast Cancer Symposium (SABCS)
Medium
Report
Abstract Describing Significant Results of Crofelemer for Cancer Therapy-Related Diarrhea in Breast Cancer Patients Accepted for Presentation at San Antonio Breast Cancer Symposium (SABCS)
Date
Time
Symbol
Company Name
Action
%Chg
Date
Time
Action
From
To
Firm
Impact
%Chg
Date
Time
Symbol
Headline
Impact
11/13
04:31 pm
jagx
Form 424B5 Jaguar Health, Inc.
Medium
Report
Form 424B5 Jaguar Health, Inc.
11/13
08:00 am
jagx
Form 8-K Jaguar Health, Inc. For: Nov 13
Medium
Report
Form 8-K Jaguar Health, Inc. For: Nov 13
11/13
06:32 am
jagx
Form 10-Q Jaguar Health, Inc. For: Sep 30
Medium
Report
Form 10-Q Jaguar Health, Inc. For: Sep 30
10/10
09:58 pm
jagx
Form 4 Jaguar Health, Inc. For: Oct 08 Filed by: Wolin Jonathan S.
Low
Report
Form 4 Jaguar Health, Inc. For: Oct 08 Filed by: Wolin Jonathan S.
10/10
09:58 pm
jagx
Form 4 Jaguar Health, Inc. For: Oct 08 Filed by: Lizak Carol R.
Low
Report
Form 4 Jaguar Health, Inc. For: Oct 08 Filed by: Lizak Carol R.
10/10
09:58 pm
jagx
Form 4 Jaguar Health, Inc. For: Oct 08 Filed by: Chaturvedi Pravin R
Low
Report
Form 4 Jaguar Health, Inc. For: Oct 08 Filed by: Chaturvedi Pravin R
10/10
09:56 pm
jagx
Form 4 Jaguar Health, Inc. For: Oct 08 Filed by: CONTE LISA A
Low
Report
Form 4 Jaguar Health, Inc. For: Oct 08 Filed by: CONTE LISA A
10/10
09:55 pm
jagx
Form 4 Jaguar Health, Inc. For: Oct 08 Filed by: MICEK JOHN
Low
Report
Form 4 Jaguar Health, Inc. For: Oct 08 Filed by: MICEK JOHN
Stock Stats
| News Stats | |
|---|---|
| All News | |
| News Wires | |
| Media Monitoring | |
| SEC Edgar Filings | |
| Upgrades | |
| Downgrades | |
| Initiated | |
| Reiterated | |
| Last Earnings | |
| Last Earnings EPS | |
| Next Earnings | |
| Order Stats |
|---|
| Sub-Penny |
|
|
| Odd lot |
|
|
| Avg. bid-ask spread |
|
|
| Avg. bid-ask size |
|
|
| Shares at ask/bid |
|
|
| Off exchange |
|
|
Main News & Impact Reports
TOP News Gainers
6/11
Jaguar Health Subsidiary Receiving Preclinical Services Funded by the National Institute of Allergy and Infectious Diseases in Support of Development of Lechlemer Drug Product Candidate for Cholera Indication
35.0%
10/30 Jaguar Health Subsidiary Napo Pharmaceuticals Enters ex-U.S. Distribution Agreement for Mytesi (Crofelemer) with TannerGAP, Inc. 28.6%
11/12 Jaguar Health to Host Investor Call Nov. 14th at 9 a.m. Eastern Regarding Interim Analysis of HALT-D Study of Mytesi (Crofelemer) for Prevention of Diarrhea in Breast Cancer Patients, Q3 Financials & Business Updates 25.7%
12/31 Jaguar Health Inc (NASDAQ: JAGX) was upgraded by analysts at Zacks Investment Research from a "sell" rating to a "hold" rating. 17.8%
9/30 Jaguar Health Subsidiary Receives Notice of Allowance from Canadian Intellectual Property Office for Patent Application 12.0%
9/12 Jaguar Health Inc (NASDAQ: JAGX) is now covered by analysts at LADENBURG THALM/SH SH. They set a "buy" rating on the stock. 10.8%
8/20 Form 3 Jaguar Health, Inc. For: Aug 13 Filed by: Lizak Carol R. 10.3%
6/24 Jaguar Health Regains Compliance with All Applicable Nasdaq Stock Market Listing Standards 9.5%
9/16 Jaguar Health's Mytesi Drug Product Now Approved for Sale in Puerto Rico 8.3%
12/26 Form 8-K Jaguar Health, Inc. For: Dec 20 6.9%
10/30 Jaguar Health Subsidiary Napo Pharmaceuticals Enters ex-U.S. Distribution Agreement for Mytesi (Crofelemer) with TannerGAP, Inc. 28.6%
11/12 Jaguar Health to Host Investor Call Nov. 14th at 9 a.m. Eastern Regarding Interim Analysis of HALT-D Study of Mytesi (Crofelemer) for Prevention of Diarrhea in Breast Cancer Patients, Q3 Financials & Business Updates 25.7%
12/31 Jaguar Health Inc (NASDAQ: JAGX) was upgraded by analysts at Zacks Investment Research from a "sell" rating to a "hold" rating. 17.8%
9/30 Jaguar Health Subsidiary Receives Notice of Allowance from Canadian Intellectual Property Office for Patent Application 12.0%
9/12 Jaguar Health Inc (NASDAQ: JAGX) is now covered by analysts at LADENBURG THALM/SH SH. They set a "buy" rating on the stock. 10.8%
8/20 Form 3 Jaguar Health, Inc. For: Aug 13 Filed by: Lizak Carol R. 10.3%
6/24 Jaguar Health Regains Compliance with All Applicable Nasdaq Stock Market Listing Standards 9.5%
9/16 Jaguar Health's Mytesi Drug Product Now Approved for Sale in Puerto Rico 8.3%
12/26 Form 8-K Jaguar Health, Inc. For: Dec 20 6.9%
TOP News Decliners
11/14
Jaguar Health Inc (NASDAQ: JAGX) was upgraded by analysts at ValuEngine from a "hold" rating to a "buy" rating.
-28.8%
4/16 Form 8-K Jaguar Health, Inc. For: Apr 15 -22.1%
8/14 Form 10-Q Jaguar Health, Inc. For: Jun 30 -20.9%
6/6 Jaguar Health, Inc. Announces 1-for-70 Reverse Stock Split -19.0%
3/23 Form 8-K Jaguar Health, Inc. For: Mar 21 -19.0%
7/5 Form FWP Jaguar Health, Inc. Filed by: Jaguar Health, Inc. -15.1%
9/24 Form 8-K Jaguar Health, Inc. For: Sep 24 -12.9%
5/11 Jaguar Health readies $10M equity offering [Seeking Alpha] -12.6%
7/15 Form S-1/A Jaguar Health, Inc. -12.4%
10/1 Jaguar Health Files Final Canalevia (Crofelemer) Technical Section for Proposed Indication of Chemotherapy-Induced Diarrhea in Dogs -12.2%
4/16 Form 8-K Jaguar Health, Inc. For: Apr 15 -22.1%
8/14 Form 10-Q Jaguar Health, Inc. For: Jun 30 -20.9%
6/6 Jaguar Health, Inc. Announces 1-for-70 Reverse Stock Split -19.0%
3/23 Form 8-K Jaguar Health, Inc. For: Mar 21 -19.0%
7/5 Form FWP Jaguar Health, Inc. Filed by: Jaguar Health, Inc. -15.1%
9/24 Form 8-K Jaguar Health, Inc. For: Sep 24 -12.9%
5/11 Jaguar Health readies $10M equity offering [Seeking Alpha] -12.6%
7/15 Form S-1/A Jaguar Health, Inc. -12.4%
10/1 Jaguar Health Files Final Canalevia (Crofelemer) Technical Section for Proposed Indication of Chemotherapy-Induced Diarrhea in Dogs -12.2%
Don’t Miss Out On The Next BIG Stock Move
Never get left behind with our daily ‘Shakers & Movers’ newsletter. Discover the biggest gainer or loser in the stock market, and learn exactly WHY it moved. To find out which one caught Wall Street by surprise TODAY, sign up to our newsletter below: